
Opinion|Videos|March 25, 2024
Widening the Therapeutic Window in The Management of Parkinson’s Disease
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
Episodes in this series
Timecodes:
1:20 Long-term challenges
2:58 Fluctuations in benefits
6:35 Therapeutic window
11:40 Amantadine ER for PD
14:33 Dyskinesia and treatment
18:18 Amantadine patients
23:14 Amantadine formulations
27:59 Early treatment & future
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy
2
Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits
3
Enhancing Biomarker Use and Targeted Treatment Approaches in Alzheimer Disease: Aaron Burstein, PharmD
4
What the EC Decision on High-Dose Spinraza Means for SMA Care
5





























